Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:08 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 2,021 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Initial Surgery Clear all
Completed Not applicable Interventional

Brief Behavioral Treatment of Insomnia in Military Veterans: Phase 2 (BBTIMVII)

NCT00840255
View directory record Official record
Conditions
Chronic Insomnia
Interventions
BBTI-MV, Information Control
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Nov 1, 2026, 5:08 AM EST
Completed Phase 3 Interventional

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

NCT02932618
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Vonicog alfa, Antihemophilic Factor (Recombinant)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
16
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 1, 2026, 5:08 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility and Preliminary Efficacy of Support Figure Attendance at Bariatric Patients' Clinical Visits

NCT03642197
View directory record Official record
Conditions
Obesity, Morbid, Bariatric Surgery Candidate, Diet Habit, Behavior, Social, Physical Activity
Interventions
Attendance
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Nov 1, 2026, 5:08 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

NCT00892723
View directory record Official record
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Pasadena, California • Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Nov 1, 2026, 5:08 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

NCT01991379
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor (GIST)
Interventions
MEK162, Imatinib Mesylate (Gleevec®; STI571; NSC #716051), Blood draws, biopsy
Drug · Other · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Nov 1, 2026, 5:08 AM EST
Completed Phase 1 Interventional Results available

IDH1 Peptide Vaccine for Recurrent Grade II Glioma

NCT02193347
View directory record Official record
Conditions
Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor, Cancer of the Brain
Interventions
PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid (Td), Temozolomide
Biological · Drug
Lead sponsor
Katy Peters, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Nov 1, 2026, 5:08 AM EST
Completed No phase listed Observational

Rib Fracture Cryoanalgesia

NCT06093776
View directory record Official record
Conditions
Pain Management Improvement
Interventions
ioveraº system
Device
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 1, 2026, 5:08 AM EST
Completed Phase 2 Interventional Results available

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

NCT03367715
View directory record Official record
Conditions
MGMT-unmethylated Glioblastoma (GBM), GBM
Interventions
Nivolumab, Ipilimumab, Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Nov 1, 2026, 5:08 AM EST
Completed Not applicable Interventional

Post-op Rehabilitation's Influence on Tendon Healing & Clinical Outcomes Following Arthroscopic Rotator Cuff Repair

NCT00756015
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Early Motion Protocol, Immobilization
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Nov 1, 2026, 5:08 AM EST
Terminated Phase 4 Interventional Results available

Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles

NCT02181790
View directory record Official record
Conditions
Psoriasis, Skin or Nails
Interventions
Excimer laser, Acitretin
Device · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Nov 1, 2026, 5:08 AM EST
Completed Phase 1Phase 2 Interventional Results available

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02574078
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Bevacizumab, Pemetrexed, Best Supportive Care, nab-Paclitaxel, Paclitaxel, Docetaxel, Gemcitabine, Erlotinib, Crizotinib, Carboplatin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
133
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Nov 1, 2026, 5:08 AM EST
Completed Phase 1 Interventional

Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

NCT01011010
View directory record Official record
Conditions
Liver Cancer
Interventions
doxorubicin hydrochloride, mitomycin C, sorafenib tosylate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Nov 1, 2026, 5:08 AM EST
Recruiting Phase 1 Interventional

A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

NCT02852213
View directory record Official record
Conditions
AADC Deficiency
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
24 Months and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
3
States / cities
San Francisco, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 1, 2026, 5:08 AM EST
Recruiting Phase 3 Interventional

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

NCT06724237
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
Procedure · Other · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2075
U.S. locations
164
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 5:08 AM EST
Recruiting Phase 2 Interventional

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

NCT05317000
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Combination 5-azacytidine and nivolumab, Nivolumab
Drug
Lead sponsor
Barbara Burtness
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Nov 1, 2026, 5:08 AM EST
Terminated Phase 4 Interventional Accepts healthy volunteers

Non-surgical Alternatives to Treatment of Failed Medical Abortion

NCT02704481
View directory record Official record
Conditions
Abortion Failure
Interventions
Mifepristone, Misoprostol, Placebo mifepristone, Placebo misoprostol
Drug
Lead sponsor
Gynuity Health Projects
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
14
States / cities
Concord, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Nov 1, 2026, 5:08 AM EST
Suspended Phase 2 Interventional

Methimazole in Patients With Progressive Glioblastoma

NCT05607407
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
Methimazole, Recurrent Glioblastoma Surgical Resection, Pharmacodynamic Assays
Drug · Procedure · Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 1, 2026, 5:08 AM EST
Completed Early Phase 1 Interventional

Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

NCT04057053
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Cataract
Interventions
Netarsudil 0.02% Ophthalmic Solution
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
50 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Nov 1, 2026, 5:08 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Mechanisms and Treatment Response of Aggressive Periodontitis in Children

NCT01330719
View directory record Official record
Conditions
Aggressive Periodontitis
Interventions
Diseased periodontal treatment, Conventional periodontal treatment
Procedure
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 90 Years
Enrollment
514 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2022
U.S. locations
10
States / cities
Brooker, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Nov 1, 2026, 5:08 AM EST
Terminated Phase 2 Interventional Results available

Oral ONC201 in Adult Recurrent Glioblastoma

NCT02525692
View directory record Official record
Conditions
Glioblastoma, Diffuse Midline Glioma, H3 K27M Glioma, Thalamic Glioma, Infratentorial Glioma, Basal Ganglia Glioma
Interventions
Dordaviprone (ONC201)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
16 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Nov 1, 2026, 5:08 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA

NCT04589611
View directory record Official record
Conditions
Osteoarthritis, Post-traumatic Osteoarthritis
Interventions
amobarbital/Gel-One (one dose), Placebo (single dose), amobarbital/Gel-One (two doses), Placebo (two doses)
Drug
Lead sponsor
J L Marsh
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 1, 2026, 5:08 AM EST
Terminated Not applicable Interventional Results available

Blood Flow Restriction Training in ACL Surgery

NCT05245864
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries
Interventions
blood flow restriction, physical therapy standard of care
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 34 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Nov 1, 2026, 5:08 AM EST
Completed Phase 3 Interventional Results available

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

NCT00567567
View directory record Official record
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate Liposome
Procedure · Drug · Radiation + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
169
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 128 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Nov 1, 2026, 5:08 AM EST
Completed Not applicable Interventional Results available

Unmet Social Needs Study

NCT04977583
View directory record Official record
Conditions
Cardiovascular Disease, Hypertension, Diabetes Mellitus, Hyperlipidemia
Interventions
Unmet Need Screening, Unmet Need Referral - Resource Sheet, Unmet Need Referral Assistance
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Nov 1, 2026, 5:08 AM EST